Short-term treatment with SGLT2 inhibitors acutely reduces arterial stiffness in patients with type 2 diabetes receiving either dapagliflozin or empagliflozin; however, in our study, empagliflozin demonstrated a more significant and faster effect than dapagliflozin, underlining the potential vascular benefits beyond glucose control of SGLT2 inhibitors, particularly related to vascular stiffness, and this may represent an additional benefit in the clinical setting. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.